• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Live Attenuated Influenza Vaccine (Fluenz?): A Guide to its Use in the Prevention of Seasonal Influenza in Children in the EU

tetano

Editor, Senior Moderator
Paediatr Drugs. 2012 Aug 1;14(4):271-9. doi: 10.2165/11207080-000000000-00000.
Live Attenuated Influenza Vaccine (Fluenz?): A Guide to its Use in the Prevention of Seasonal Influenza in Children in the EU.
Scott LJ, Carter NJ, Curran MP.
Source

Adis, Auckland, New Zealand.
Abstract

Live attenuated influenza vaccine (LAIV).[Fluenz?] has a convenient intranasal route of administration. In the EU, it is indicated for the prevention of influenza disease caused by the influenza virus strains contained in the vaccine in children and adolescents aged 2 years to <18 years. The vaccine elicits a high immunogenic response, is protective against seasonal influenza infection and is associated with the development of herd immunity. LAIV is generally well tolerated, with the safety of the vaccine in the approved pediatric population generally considered to be similar to that of placebo based on clinical trials and extensive experience involving more than 39 million vaccine doses.

PMID:
22702743
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/22702743
 
Back
Top Bottom